Nontuberculous mycobacteria

Current Opinion in Pulmonary Medicine

Volumn 3, Issue 2, 1997, Pages 139-145

  Griffith, David E ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CLARITHROMYCIN; TUBERCULOSTATIC AGENT;

AIDS RELATED COMPLEX; ATYPICAL MYCOBACTERIOSIS; HUMAN; LUNG TUBERCULOSIS; REVIEW;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; CLARITHROMYCIN; HUMANS; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; MYCOBACTERIUM INFECTIONS, ATYPICAL; TUBERCULOSIS, PULMONARY;

EID: 0031085340     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199703000-00010     Document Type: Article

References (37)

1. Prince DS, Peterson DD, Steinger RM, Gottlieb JB, Scott R, Israel HL, Figueroa WG, Fish JE: Infection with Mycobacterium avium complex in patients without redisposing on conditions. N Engl J Med 1989, 321:863-868.
2. Griffith DE, Girard WM, Wallace RJ Jr: Clinical features of pulmonary disease caused by rapidly growing mycobacteria. Am Rev Respir Dis 1993, 147:1271-1278.
3. Griffith DE, Wallace RJ Jr: New developments in the treatment of nontuberculous mycobacterial (NTM) disease. Semin Respir Infect 1996, 11:301-310.
4. Eisenberg E, Barza M: Azithromycin and clarithromycin. Current Clinical Topics Infectious Disease. Cambridge, MA. Blackwell Scientific Publications; 1994:52-78.
5. Periti P, Mazzei T, Mini E, Novelli A: Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992, 23:106-131.
6. The DATRI study group: Coadministration of a clarithromycin alters the concentration-time profile of rifabutin [abstract A2]. In Program and Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy: Orlando, FL, October, 1994.
7. Chaisson RE, Benson CA, Dube MP, Heifits L, Korvick J, Elkin S, Smith T, Craft J, Sattler F, the AIDS Clinical Trials Group Protocol 157 study team: Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. Ann Intern Med 1994, 121:905-911.
8. Shafran S, Singer J, Zarowny DP, Phillips P, Salit I, Walmsley S, Fong F, Gill M, Rachus A, Lalonde R: A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996, 335:377-383. Established clarithromycin, rifabutin, and ethambutol as the regimen of choice for treatment of disseminated MAC in AIDS.
9. Abrams DI, Mitchell TF, Child CC, Shiboski SC, Brosgart CL, Mass MM, the Community Consortium: Clofazimine as prophylaxis for disseminated Mycobacterium avium complex infection in AIDS. J Infect Dis 1993, 167:1459-1463.
10. Kemper CA, Havlir D, Haghighat D, Dube M, Bartok AE, Sison JP, Yao Y, Yangco B, Leedom JM, Tilles JG, et al.: The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. J Infect Dis 1994, 170:157-164.
11. Killian AD, Drusano GL, Kanyok TP: Pharmacokinetics of drugs used for the therapy of Mycobacterium avium-complex infection. Lung Biol Health Dis 1996, 87:197-240.
12. Pierce M, Crampton S, Henry D, LaMarca A, Montecalvo M, Wormser G, Jablonowski H, Yangco BG, Jemsek J, Cynamon M, et al.: A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced Acquired Immunodeficiency Syndrome. N Engl J Med 1996, 335:384-391. Demonstrated that clarithromycin was effective as prophylaxis against disseminated MAC in AIDS. If MAC disease developed in patients who received clarithromycin, it was macrolide resistant.
13. Havlir D, Dube M, Sattler F, Forthal D, Kemper C, Dunne M, Parenti D, Lavelle J, White A, Witt M, et al.: Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996, 335:392-398. Demonstrated that weekly azithromycin was effective as prophylaxis against dissmeninated MAC. Combined weekly azithromycin and daily rifabutin was the most effective prophylaxis regimen so far tested but also was associated with frequent toxicity.
14. Nightingale SD, Cameron DW, Gordin FM, Sullam P, Cohn D, Chaisson R, Eron L, Sparti P, Bihari B, Kaufman D: Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993, 329:828-833.
15. Moore RD, Chaisson RE: Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. AIDS 1995, 9:1337-1342.
16. Bishai WR, Graham N MH, Harrington S, Page C, Moore-Rice K, Hooper N, Chaisson RE: Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. N Engl J Med 1996, 334:1573-1576. Demonstrated that patients with active tuberculosis also receiving rifabutin prophylaxis against disseminated MAC could develop rifampin-resistant tuberculosis.
17. Centers for Disease Control: Impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR Morb Mortal Wkly Rep 1996, 45:921-927. Discusses the options for the use of rifamycins (rifampin and rifabutin) with protease inhibitors. In general, rifampin is contraindicated and rifabutin must be used at lower doses and with caution.
18. Kalayjian RC, Toossi Z, Tomashefski JF Jr, Carey J, Ross J, Tomford J, Blinkhorn R: Pulmonary disease due to infection by Mycobacterium avium complex in patients with AIDS. Clin Infect Dis 1995, 20:1186-1194.
19. Dautzenberg B, Piperson D, Diot P, Truffot-Pernot C, Chauvin J, and the Clarithromycin Study Group of France: Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest 1995, 107:1035-1040.
20. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Murphy D, Onyi G, Steingrube V, Mazurek G: Initial Clarithromycin monotherapy for Mycobacterium avium-intracellular complex lung disease. Am J Respir Crit Care Med 1994, 149:1835-1841.
21. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Murphy D: Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med 1996, 153:1766-1772. Established clarithromycin, rifabutin (or rifampin) and ethambutol as the treatment of choice for pulmonary MAC disease.
22. Woodley CL, Kilburn JO: In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin. Am Rev Respir Dis 1982, 126:586-587.
23. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K: Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995, 171:747-750.
24. Griffith DE, Brown BA, Girard WM, Murphy DT, Wallace RJ Jr: Azithromycin activity against Mycobacterium avium complex lung disease in HIV negative patients. Clin Infect Dis 1996, 23:983-989. Azithromycin has comparable activity to clarithromycin in the initial portion of therapy for MAC lung disease.
25. Wallace RJ Jr, Brown BA, Griffith DE: Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993, 16:215-221.
26. Griffith DE, Brown BA, Girard WM, Wallace RJ Jr: Adverse events associated with high dose rifabutin in macrolide-containing regimens for Mycobacterium avium complex lung disease. Clin Infect Dis 1995, 21:594-598. Rifabutin at 600 mg/d in macrolide-containing regimens for MAC lung disease was associated with frequent and sometimes severe adverse events, including leukopenia, polyarthralgia, and uveitis.
27. Griffith DE, Brown BA, Wallace RJ Jr: Varying doses of rifabutin affect white blood cell and platelet counts in Human Immunodeficiency Virus-negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease. Clin Infect Dis 1996, 23:1321-1322.
28. Iseman M, Madsen L, Goble M, Pomerantz M: Surgical intervention in pulmonary disease due to mycobacteria other than tuberculosis (MOTT) [abstract]. World Conf Lung Health Suppl ARRD 1990, 141:A616.
29. Parrot RG, Grosset JH: Post-surgical outcome of 57 patients with Mycobacterium xenopi pulmonary infection. Tubercle 1988, 69:47-55.
30. Holland SM, Eisenstein EM, Kuhns DB, Turner ML, Fleisher TA, Strober W, Gallin JI: Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. N Engl J Med 1994, 330:1348-1355.
31. Wolinsky E: Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. Clin Infect Dis 1995, 20:954-963.
32. Tunkel DE, Romaneschi KB: Surgical treatment of cervicofacial nontuberculous mycobacterial adenitis in children. Laryngoscope 1995, 105:1024-1028.
33. Berger C, Pfyffer GE, Nadal D: Treatment of nontuberculous mycobacterial lymphadenitis with clarithromycin plus rifabutin. J Pediatr 1996, 128:383-386. Clarithromycin and rifabutin were effective for treatment of MAC lymphadenitis for children who could not be adequately treated with surgery.
34. Valero G, Peters J, Jorgensen JH, Graybill JR: Clinical isolates of Mycobacterium simiae in San Antonio, Texas. Am J Respir Crit Care Med 1995, 152:1555-1557. Mycobacterium simiae is infrequently a significant pathogen, especially when isolated from the sputum. However, recovery of this organism from blood cultures in patients with AIDS is more significant. Treatment with a macrolide-containing regimen appears to be effective.
35. Pechere M, Opravil M, Wald A, Chave JP, Bessesen M, Sievers A, Hein R, Overbeck J, Clark RA, Tortoli E, Emler S, Kirschner P, Gabriel V, Bottger EC, Hirschel B, the Swiss HIV Cohort Study: Clinical and epidemiologic features of infection with Mycobacterium genavense. Arch Intern Med 1995, 155:400-404.
36. Wallace RJ Jr, O'Brien R, Glassroth J, Raleigh J, Dutt A: Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis 1990, 142:940-953.
37. Sauret J, Hernandez-Flix S, Castro E, Hernandez L, Ausina V, Coll P: Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy. Tubercle Lung Dis 1995, 76:104-108.